Source-grounded facts extracted from Fuse Medical, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Fuse Medical, Inc. reported second quarter ending June 30, 2023 results: revenue $5.0 million, net income $307,588.
“quarter ended June 30, 2023 with the Securities and Exchange Commission (“SEC”). Second Quarter 2023 Financial Highlights ● Net revenues for the quarter ended June 30, 2023 were $5.0 million, compared to $4.7 million for the quarter ended June 30, 2022 which was an increase of approximately 7%. ● For the quarter ended June 30, 2023, gross profit was $3.5 million, or”
Fuse Medical, Inc. shareholders approved Ratification of the Selection of M&K CPAS, PLLC at the 2023-06-23 meeting.
“The selection of M&K to act as an independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023 was ratified by a vote of (i) 64,474,346 in favor, (ii) 47,224 against, and (iii) 191 abstaining.”
Fuse Medical, Inc. shareholders approved Election of Board of Directors at the 2023-06-23 meeting.
“The following persons were elected as directors of the Company for a one-year term expiring at the 2024 Annual Meeting of Stockholders with the following vote: Name Votes For Votes Against Votes Withheld Broker Non-Votes Renato V. Bosita, Jr., MD 63,087,944 61,351 2 1,372,464 Mark W. Brooks 63,132,848 16,447 2 1,372,464 Lawrence S. Yellin 63,091,848 57,447 2 1,372,464 Christopher C. Reeg 63,132,854 16,441 2 1,372,464”
Fuse Medical, Inc. reported the year ended December 31, 2022 results: revenue $18.6 million, net income $3.1 million.
“Net revenues for the year ended December 31, 2022 were $18.6 million”
Fuse Medical, Inc. engaged M&K PLLC as its auditor.
“On November 17, 2022, the Board approved the appointment of M&K PLLC (“M&K”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.”
Fuse Medical, Inc. reported third quarter ended September 30, 2022 results: revenue $4.5 million, net income net loss was $9,376.
“Net revenues for the quarter ended September 30, 2022 were $4.5 million, compared to $4.2 million for the quarter ended September 30, 2021 which was an increase of approximately 7%.”
John S. Gross departed as Interim Chief Financial Officer at Fuse Medical, Inc..
“Effective April 4, 2022, John S. Gross ceased providing the Company with interim CFO services pursuant to the Company’s engagement agreement with CFO Consulting Partners, LLC.”
Lawrence S. Yellin was appointed as Director at Fuse Medical, Inc..
“Effective April 4, 2022, the Board of Directors of the Company (the “Board”) has appointed Lawrence S. Yellin as Chief Financial Officer (CFO) and Treasurer of the Company and as a member of the Board.”
Lawrence S. Yellin was appointed as Chief Financial Officer and Treasurer at Fuse Medical, Inc..
“Effective April 4, 2022, the Board of Directors of the Company (the “Board”) has appointed Lawrence S. Yellin as Chief Financial Officer (CFO) and Treasurer of the Company and as a member of the Board.”
William E. McLaughlin, III resigned as Chief Financial Officer and Director at Fuse Medical, Inc..
“On November 29, 2021, William E. McLaughlin, III resigned as Chief Financial Officer and as a Director of the Board of Fuse Medical, Inc. (the “Company”) as well as from all other positions Mr. McLaughlin held with the Company and its subsidiaries.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.